Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2070 Phase 1 SAD in Healthy Subjects
NCT07241923Phase 1Recruiting
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertriglyceridemia and mixed hyperlipidemia comparing SYH2070 experimental group with Placebo group (2 arms). Primary endpoint: Number of Subjects with Adverse Events as Assessed by CTCAE v5.0. Started Nov 2025; status: recruiting.
02
Drugs
SYH2070
03
Conditions
hypertriglyceridemiamixed hyperlipidemia
Beyond the preview
Go deeper on NCT07241923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241923.